Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Oxygen
Accession Number
DB09140
Type
Small Molecule
Groups
Approved, Vet approved
Description

Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow resistance in the diseased lung, leading to decreased cardiovascular workload in an attempt to oxygenate the lungs. Oxygen therapy is used to treat emphysema, pneumonia, some heart disorders (congestive heart failure), some disorders that cause increased pulmonary artery pressure, and any disease that impairs the body's ability to take up and use gaseous oxygen. Higher level of oxygen than ambient air (hyperoxia) can be introduced under normobaric or hyperbaric conditions.

Structure
Thumb
Synonyms
  • Dioxygen
  • Molecular oxygen
  • Oxigeno gaseoso
  • Oxygen USP
  • Pure oxygen
External IDs
E-948 / INS NO.948 / INS-948
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AirGas210 mL/1LRespiratory (inhalation)Airgas Usa, Llc1997-11-062014-03-31Us
AirGas210 mL/1LRespiratory (inhalation)Airgas Usa, Llc1997-11-06Not applicableUs
AirGas210 mL/1LRespiratory (inhalation)Djb Gas Services, Inc2017-11-07Not applicableUs
AirGas195 mL/1000mLRespiratory (inhalation)Industrial Gas Distributors Inc1987-04-012015-12-29Us
AirGas210 mL/1LRespiratory (inhalation)Roberts Oxygen Company, Inc.1967-01-01Not applicableUs
AirGas210 mL/1LRespiratory (inhalation)Syoxsa, Inc.2018-11-30Not applicableUs
AirGas210 mL/1LRespiratory (inhalation)Andy-Oxy Co., Inc.2007-01-01Not applicableUs
AirGas210 mL/1LRespiratory (inhalation)Haun Specialty Gases, Inc.2005-01-04Not applicableUs
AirGas210 mL/1LRespiratory (inhalation)Hartman Brothers, Inc.1977-07-01Not applicableUs
AirGas210 mL/1LRespiratory (inhalation)Central Welding Supply Company2015-11-15Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
OxygenGas992 mL/1LRespiratory (inhalation)Arkansas Welding & Industrial Supply2001-10-20Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Air USPOxygen (19.5 %) + Nitrogen (80.5 %)GasRespiratory (inhalation)Praxair, Inc.1993-12-31Not applicableCanada
Alnox GasOxygen (50 %) + Nitrous oxide (50 %)GasRespiratory (inhalation)Air Liquide Canada Inc.1995-12-31Not applicableCanada
CarbogenOxygen (50 %) + Carbon dioxide (50 %)GasRespiratory (inhalation)Linde Llc1995-12-31Not applicableCanada
Carbon Dioxide 1% W OxygenOxygen (93 %) + Carbon dioxide (7 %)GasRespiratory (inhalation)Liquid Carbonic Inc.1990-12-311998-06-09Canada
Carbon Dioxide 12.1% W OxygenOxygen (77 %) + Carbon dioxide (23 %)GasRespiratory (inhalation)Praxair, Inc.1990-12-31Not applicableCanada
Carbon Dioxide 23.1% W OxygenOxygen (50 %) + Carbon dioxide (50 %)GasRespiratory (inhalation)Praxair, Inc.1990-12-31Not applicableCanada
Carbon Dioxide 7.1% W OxygenOxygen (88 %) + Carbon dioxide (12 %)GasRespiratory (inhalation)Praxair, Inc.1990-12-31Not applicableCanada
Carbon Dioxide In Oxygen MixtureOxygen (90 %) + Carbon dioxide (10 %)GasRespiratory (inhalation)Matheson Gas Products Canada Inc.1983-12-311997-12-24Canada
Carbon Dioxide MixtureOxygen (23 %) + Carbon dioxide (12 %) + Nitrogen (65 %)GasRespiratory (inhalation)Liquid Carbonic Inc.1990-12-311998-06-09Canada
Carbon Dioxide USP, Oxygen USP Medical G.M.Oxygen (93 %) + Carbon dioxide (7 %)GasRespiratory (inhalation)Praxair, Inc.1993-12-31Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
AirOxygen (23 L/100L) + Nitrogen (77 L/100L)GasRespiratory (inhalation)Air Liquide Canada Inc.1960-01-01Not applicableUs
AirOxygen (210 mL/1L)GasRespiratory (inhalation)Praxair, Puerto Rico Inc.2005-10-01Not applicableUs
AirOxygen (210 mL/1L)GasRespiratory (inhalation)Airgas Usa, Llc1997-11-062014-03-31Us
AirOxygen (195 mL/1000mL)GasRespiratory (inhalation)Industrial Gas Distributors Inc1987-04-012015-12-29Us
AirOxygen (99 L/100L) + Nitrogen (99 L/100L)GasRespiratory (inhalation)Air Liquide Canada Inc.1960-01-012010-06-15Us
AirOxygen (20.9 L/100L)GasRespiratory (inhalation)Indianapolis Welding Supply, Inc1972-01-012013-04-12Us
AirOxygen (210 mL/1L)GasRespiratory (inhalation)Airgas Mid South, Inc.1997-11-062010-03-02Us
Air CompressedOxygen (20 L/100L)GasRespiratory (inhalation)Specialty Gases Of America1995-01-012015-06-10Us
Air Compressed Medical AirOxygen (21 L/100L)GasRespiratory (inhalation)Vagabond Welding Supply2013-04-01Not applicableUs
CarbogenOxygen (95 mL/1L) + Carbon dioxide (5 mL/1L)GasRespiratory (inhalation)WestAir Gases and Equipment, Inc.2000-01-01Not applicableUs
Categories
UNII
S88TT14065
CAS number
7782-44-7
Weight
Average: 31.9988
Monoisotopic: 31.989829244
Chemical Formula
O2
InChI Key
MYMOFIZGZYHOMD-UHFFFAOYSA-N
InChI
InChI=1S/O2/c1-2
IUPAC Name
oxidanone
SMILES
O=O

Pharmacology

Indication

Oxygen therapy in clinical settings is used across diverse specialties, including various types of anoxia, hypoxia or dyspnea and any other disease states and conditions that reduce the efficiency of gas exchange and oxygen consumption such as respiratory illnesses, trauma, poisonings and drug overdoses. Oxygen therapy tries to achieve hyperoxia 6 to reduce the extent of hypoxia-induced tissue damage and malfunction.

Pharmacodynamics

Oxygen therapy improves effective cellular oxygenation, even at a low rate of tissue perfusion. Oxygen molecules adjust hypoxic ventilatory drive by acting on chemoreceptors on carotid bodies that sequentially relay sensory information to the higher processing centers in brainstem. It also attenuates hypoxia-induced mitochondrial depolarization that generates reactive oxygen species and/or apoptosis. Studies investigating on hyperbaric oxygen therapy has shown that oxygen supplementation can induce neural stem cell proliferation in neonatal rats thus promoting neurological regeneration after injuries 3. CD34+, CD45-dim leukocytes are also potential targets for hyperbaric oxygen therapy benefit as their mobilization was increased in vitro which could facilitate the acceleration of recovery at peripheral sites 1.

Mechanism of action

Oxygen therapy increases the arterial pressure of oxygen and is effective in improving gas exchange and oxygen delivery to tissues, provided that there are functional alveolar units. Oxygen plays a critical role as an electron acceptor during oxidative phosphorylation in the electron transport chain through activation of cytochrome c oxidase (terminal enzyme of the electron transport chain). This process achieves successful aerobic respiration in organisms to generate ATP molecules as an energy source in many tissues. Oxygen supplementation acts to restore normal cellular activity at the mitochondrial level and reduce metabolic acidosis. There is also evidence that oxygen may interact with O2-sensitive voltage-gated potassium channels in glomus cells and cause hyperpolarization of mitochondrial membrane 4.

TargetActionsOrganism
UCytochrome c oxidase subunit 1
agonist
activator
Humans
UNADPH oxidase 1
agonist
activator
Humans
UHemoglobin subunit alphaNot AvailableHumans
UHemoglobin subunit betaNot AvailableHumans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

Oxygen binds to oxygen-carrying protein in red blood cells called hemoglobin with high affinity. The amount of oxygen molecules bound to the fixed amount of circulating hemoglobin in the blood determines the overall oxygen saturation level and this oxygen-delivering capacity is regulated by Bohr effect.

Metabolism
Not Available
Route of elimination

Exhalation

Half life

Approximately 122.24 seconds

Clearance
Not Available
Toxicity

May cause burns or frostbites in case of eye or skin contact with rapidly expanding gas. Oxygen therapy can induce hypercapnic respiratory failure in patients with respiratory diseases and musculoskeletal diseases in upper airways. Sudden cessation of oxygen supplementation in these patients can further lead to rebound hypoxaemia. In patients with mild or moderate strokes, hyperoxaemia may cause absorption atelectasis or myocardial infarction. Oxygen content should be monitored following the administration to verify therapeutic benefit.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
  1. Heyboer M 3rd, Milovanova TN, Wojcik S, Grant W, Chin M, Hardy KR, Lambert DS, Logue C, Thom SR: CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen - changes with oxygen dosage. Stem Cell Res. 2014 May;12(3):638-45. doi: 10.1016/j.scr.2014.02.005. Epub 2014 Feb 28. [PubMed:24642336]
  2. Prabhakar NR: Oxygen sensing by the carotid body chemoreceptors. J Appl Physiol (1985). 2000 Jun;88(6):2287-95. [PubMed:10846047]
  3. Feng Z, Liu J, Ju R: Hyperbaric oxygen treatment promotes neural stem cell proliferation in the subventricular zone of neonatal rats with hypoxic-ischemic brain damage. Neural Regen Res. 2013 May 5;8(13):1220-7. doi: 10.3969/j.issn.1673-5374.2013.13.007. [PubMed:25206416]
  4. Lopez-Barneo J, Gonzalez-Rodriguez P, Gao L, Fernandez-Aguera MC, Pardal R, Ortega-Saenz P: Oxygen sensing by the carotid body: mechanisms and role in adaptation to hypoxia. Am J Physiol Cell Physiol. 2016 Apr 15;310(8):C629-42. doi: 10.1152/ajpcell.00265.2015. Epub 2016 Jan 13. [PubMed:26764048]
  5. Liu W, Khatibi N, Sridharan A, Zhang JH: Application of medical gases in the field of neurobiology. Med Gas Res. 2011 Jun 27;1(1):13. doi: 10.1186/2045-9912-1-13. [PubMed:22146102]
  6. British Thoracic Society: Guideline for emergency oxygen use in adult patients [Link]
  7. Airgas SDS [Link]
  8. Linde SDS [Link]
External Links
Human Metabolome Database
HMDB0001377
KEGG Drug
D00003
KEGG Compound
C00007
PubChem Compound
977
PubChem Substance
310265054
ChemSpider
952
ChEBI
27140
ChEMBL
CHEMBL1234886
PharmGKB
PA450744
HET
OXY
Drugs.com
Drugs.com Drug Page
Wikipedia
Oxygen
ATC Codes
V03AN01 — Oxygen
AHFS Codes
  • 92:00.00 — Miscellaneous Therapeutic Agents
  • 92:92.00 — Other Miscellaneous Therapeutic Agents
PDB Entries
1a4f / 1a6m / 1ash / 1b86 / 1dcc / 1dp6 / 1dz8 / 1e5d / 1f65 / 1faw
show 383 more
MSDS
Download (177 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Unknown StatusTreatmentPain, Neuropathic1
1CompletedDiagnosticAsthma / Chronic Obstructive Pulmonary Disease (COPD) / Cystic Fibrosis (CF) / Emphysema / Small Airways Disease1
1CompletedHealth Services ResearchArterial hypoxia / Hypercapnia1
1RecruitingHealth Services ResearchRespiratory Depression1
1TerminatedDiagnosticNeoplasms1
1TerminatedTreatmentCluster Headache1
1, 2CompletedTreatmentAirway Obstruction / Dyspnea1
1, 2RecruitingTreatmentHypoplastic Left Heart Syndrome (HLHS)1
1, 2TerminatedTreatmentAcidosis, Respiratory / Chronic Lung Diseases / Hypoxemia1
1, 2WithdrawnTreatmentChronic Obstructive Airway Disease (COPD) With Co-existent Obstructive Sleep Apnea (Overlap Syndrome) / Chronic Obstructive Pulmonary Disease (COPD)1
2Active Not RecruitingTreatmentLymphedema, Secondary1
2CompletedSupportive CarePulmonary Fibrosis1
2CompletedTreatmentCystic Fibrosis (CF)1
2CompletedTreatmentHeart Arrest1
2CompletedTreatmentHeart Failure1
2CompletedTreatmentMigraine1
2CompletedTreatmentOSAS (Obstructive Sleep Apneas Syndrome)1
2CompletedTreatmentPost-Concussive Symptoms / Traumatic Brain Injury (TBI)1
2CompletedTreatmentPulmonary Embolism1
2RecruitingTreatmentAcute Ischemic Stroke (AIS)1
2RecruitingTreatmentCardiac Failure / Critical Illness1
2RecruitingTreatmentOSAS (Obstructive Sleep Apneas Syndrome)1
2TerminatedNot AvailableExercise Training1
2TerminatedTreatmentLabour Pain1
2TerminatedTreatmentSickle Cell Disorders1
2TerminatedTreatmentStatus Asthmaticus1
2, 3Active Not RecruitingPreventionChronic Lung Disease of Prematurity / Infants, Premature / Intraventricular Hemorrhage / Periventricular Leukomalacia1
2, 3RecruitingPreventionCentral Nervous Injury / Decompression Sickness / Diving Medicine / Hyperbaric / Inflammatory Activity1
2, 3RecruitingTreatmentIschaemic Heart Diseases1
2, 3RecruitingTreatmentObstetrical analgesia therapy / Obstetrical Anesthesia / Postpartum Depression1
2, 3TerminatedTreatmentFebrile Convulsions1
3CompletedDiagnosticCongenital Heart Disease With Pulmonary Hypertension / Idiopathic Pulmonary Arterial Hypertension / Prophylaxis of cardiomyopathy1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Acute Myocardial Infarction (AMI) / Ischemic Reperfusion Injury / Non-ST Elevation (NSTEMI) Myocardial Infarction / ST Elevation Myocardial Infarction (STEMI) / Unstable Angina Pectoris1
3CompletedTreatmentAcute Coronary Syndromes (ACS) / Non-ST Elevation (NSTEMI) Myocardial Infarction / ST Segment Elevation Acute Myocardial Infarction / Unstable Angina Pectoris1
3CompletedTreatmentAcute Respiratory Failure / High Flow Oxygen Cannula / Immunocompromised Host1
3CompletedTreatmentBladder Cancers1
3CompletedTreatmentBronchiolitis1
3CompletedTreatmentCardiac Complications1
3CompletedTreatmentInjection Site Vesicles1
3CompletedTreatmentPeer Review, Research1
3Enrolling by InvitationTreatmentComplex Regional Pain Syndrome (CRPS)1
3RecruitingOtherVascular Diseases1
3RecruitingTreatmentCentral Sleep Apnea / Heart Failure1
3TerminatedTreatmentCongestive Heart Failure1
3TerminatedTreatmentNewborn Infants / Persistent Fetal Circulation Syndrome / Pneumonia, Aspiration / Pulmonary Hypertension (PH) / Respiratory Distress Syndrome, Newborn / Respiratory Insufficiency1
3Unknown StatusTreatmentChronic Schizophrenia1
4Active Not RecruitingTreatmentAcute Lung Injury (ALI) / Cardiopulmonary Bypass / Hyperoxia / Oxygen Toxicity / Surgery, Cardiac1
4Active Not RecruitingTreatmentInterstitial Lung Disease (ILD) / Precapillary Pulmonary Hypertension1
4CompletedBasic ScienceHyperoxia / Hypoxia, Brain / Neurobehavioral Manifestations1
4CompletedPreventionLaparotomy2
4CompletedTreatmentAcute Coronary Syndromes (ACS)1
4CompletedTreatmentAnalgesia / Bowel Cancer Screening / Colonoscopy / Entonox1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)4
4CompletedTreatmentInfants / Persistent foetal circulation disorders / Respiratory Failure1
4CompletedTreatmentST Elevation Myocardial Infarction1
4RecruitingBasic ScienceAnaesthesia therapy1
4RecruitingBasic ScienceEmphysema1
4RecruitingPreventionHypoxemic Respiratory Failure / Oxygen Toxicity1
4RecruitingPreventionPostoperative Cardiac Complication1
4RecruitingSupportive CarePrader-Willi Syndrome / Sleep Apnea, Central1
4RecruitingSupportive CareSystemic Inflammatory Response Syndrome (SIRS)1
4RecruitingTreatmentBronchiolitis1
4RecruitingTreatmentInterstitial Lung Disease (ILD) / Precapillary Pulmonary Hypertension1
4RecruitingTreatmentPatients Requiring Diagnostic Gastroscopy Suitable for Sedation / Patients Requiring Diagnostic Gastroscopy With Sedation1
4RecruitingTreatmentSepsis1
4Unknown StatusSupportive CareHealthy Volunteers1
4Unknown StatusTreatmentCardiovascular Disease (CVD) / Immune System Diseases / Nervous System Diseases / Respiratory Tract Diseases1
4Unknown StatusTreatmentPostpartum Haemorrhage (PPH)1
Not AvailableActive Not RecruitingTreatmentElectronic Fetal Monitoring / Fetal Hypoxia / Fetal-Placental Circulation1
Not AvailableCompletedNot AvailableLaparotomy1
Not AvailableCompletedBasic ScienceHealthy Volunteers / Normoxia / Systemic Hypoxia1
Not AvailableCompletedBasic ScienceResponse to Hyperoxia1
Not AvailableCompletedDiagnosticChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedPreventionPerioperative Hyperoxygenation / Wound Infections1
Not AvailableCompletedPreventionSpinal Stenosis of Lumbar Region1
Not AvailableCompletedSupportive CareCoronary Artery Disease1
Not AvailableCompletedTreatmentApnoeic Oxygenation1
Not AvailableCompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)2
Not AvailableCompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Endurance Shuttle Walking Test (Exercise at 85% of Maximal Shuttle Walking Test) / Exercise1
Not AvailableCompletedTreatmentArterial hypoxia / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedTreatmentHand Injuries/Disease Requiring Surgery to the Hand1
Not AvailableCompletedTreatmentHeadache1
Not AvailableCompletedTreatmentUpper Airway Obstruction1
Not AvailableRecruitingOtherChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingOtherCritical Illness / Respiratory Failure1
Not AvailableRecruitingPreventionSurgery, Cardiac1
Not AvailableRecruitingTreatmentAbscesses1
Not AvailableRecruitingTreatmentAbscesses / Joint dislocations / Perianal Abscess1
Not AvailableRecruitingTreatmentAcute Respiratory Distress Syndrome (ARDS)1
Not AvailableRecruitingTreatmentAortic Valve Disorder / Brain Injury / Coronary Heart Disease (CHD) / Renal Failure / Shock, Cardiogenic / Stroke1
Not AvailableRecruitingTreatmentIntermittent Hypoxemia / Primary apnea of premature newborns1
Not AvailableRecruitingTreatmentSepsis1
Not AvailableTerminatedSupportive CareChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableUnknown StatusTreatmentAnaesthesia therapy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
GasRespiratory (inhalation)195 mL/1000mL
GasRespiratory (inhalation)20.9 L/100L
GasRespiratory (inhalation)21 L/1L
GasRespiratory (inhalation)235 mL/1L
GasRespiratory (inhalation)20 %
GasRespiratory (inhalation)950 mL/1L
GasRespiratory (inhalation)50 mL/1L
GasRespiratory (inhalation)80 L/100L
GasRespiratory (inhalation)90 L/100L
GasRespiratory (inhalation)96 L/100L
GasRespiratory (inhalation)40 L/100L
GasRespiratory (inhalation)95 L/100L
GasRespiratory (inhalation)20 L/100L
GasRespiratory (inhalation)25 L/100L
GasRespiratory (inhalation)30 L/100L
GasRespiratory (inhalation)
Gas
GasRespiratory (inhalation)21 L/100L
GasRespiratory (inhalation)23 L/100L
GasCutaneous; Respiratory (inhalation)992 mL/1L
GasNasal1 L/1L
GasNasal210 mL/1L
GasNasal99 L/100L
GasNasal; Respiratory (inhalation)1 L/1L
GasNasal; Respiratory (inhalation)995 mL/1L
GasRespiratory (inhalation).99 L/1L
GasRespiratory (inhalation).995 L/1L
GasRespiratory (inhalation)100 L/99L
GasRespiratory (inhalation)1000 mL/1L
GasRespiratory (inhalation)210 mL/1L
GasRespiratory (inhalation)900 mL/1L
GasRespiratory (inhalation)93 mL/1L
GasRespiratory (inhalation)930 mL/1L
GasRespiratory (inhalation)99 L/1L
GasRespiratory (inhalation)99 mL/1L
GasRespiratory (inhalation)99 %
GasRespiratory (inhalation)99 mL/100mL
GasRespiratory (inhalation)99 L/100L
GasRespiratory (inhalation)99 L/99L
GasRespiratory (inhalation)99.0 %
GasRespiratory (inhalation)99.1 L/1L
GasRespiratory (inhalation)99.4 L/100L
GasRespiratory (inhalation)99.5 L/1L
GasRespiratory (inhalation)99.5 L/100L
GasRespiratory (inhalation)99.5 %
GasRespiratory (inhalation)99.6 L/100L
GasRespiratory (inhalation)99.6 L/1L
GasRespiratory (inhalation)99.6 %
GasRespiratory (inhalation)99.8 L/100L
GasRespiratory (inhalation)99.8 L/1L
GasRespiratory (inhalation)99.9 L/100L
GasRespiratory (inhalation)99.9 L/1L
GasRespiratory (inhalation)990 L/1L
GasRespiratory (inhalation)990 mL/1L
GasRespiratory (inhalation)990 1/1L
GasRespiratory (inhalation)991 mL/1L
GasRespiratory (inhalation)992 1/1L
GasRespiratory (inhalation)992 L/1000L
GasRespiratory (inhalation)992 mL/1L
GasRespiratory (inhalation)992 mL/1000mL
GasRespiratory (inhalation)995 mL/100L
GasRespiratory (inhalation)995 L/1L
GasRespiratory (inhalation)995 mL/1L
GasRespiratory (inhalation)996 mL/1L
GasRespiratory (inhalation)997 mL/1L
GasRespiratory (inhalation)998 mL/1L
GasRespiratory (inhalation)999 L/1000L
GasRespiratory (inhalation)999 mL/1L
LiquidRespiratory (inhalation)1.13835106 kg/1L
LiquidRespiratory (inhalation)1000 g/1L
LiquidRespiratory (inhalation)210 mg/1kg
LiquidRespiratory (inhalation)99 L/100L
LiquidRespiratory (inhalation)99 1/100L
LiquidRespiratory (inhalation)992 L/1000L
LiquidRespiratory (inhalation)995 mL/1L
LiquidRespiratory (inhalation)999 L/1000L
GasRespiratory (inhalation)992 mL/100mL
GasRespiratory (inhalation)200 mL/1L
GasRespiratory (inhalation)0.99 kg/1kg
GasRespiratory (inhalation)11321 L/11321L
GasRespiratory (inhalation)196 L/196L
GasRespiratory (inhalation)240 L/240L
GasRespiratory (inhalation)396 L/396L
GasRespiratory (inhalation)659 L/659L
GasRespiratory (inhalation)1567 L/1567L
GasRespiratory (inhalation)6931 L/6931L
GasRespiratory (inhalation)3453 L/3453L
GasRespiratory (inhalation)8688 L/8688L
GasNasal; Oral
GasRespiratory (inhalation)250 mL/1L
GasRespiratory (inhalation)300 mL/1L
GasRespiratory (inhalation)330 mL/1L
GasRespiratory (inhalation)400 mL/1L
GasRespiratory (inhalation)500 mL/1L
GasRespiratory (inhalation)600 mL/1L
GasRespiratory (inhalation)800 mL/1L
Gas; liquidRespiratory (inhalation)
GasRespiratory (inhalation)99.2 %
LiquidRespiratory (inhalation)1 L/1L
GasRespiratory (inhalation)1 L/1L
GasRespiratory (inhalation)
Prices
Not Available
Patents
Not Available

Properties

State
Gas
Experimental Properties
PropertyValueSource
melting point (°C)-218.4Airgas SDS
boiling point (°C)-183Airgas SDS
water solubility39mg/LLinde SDS
logP0.65SDS
Predicted Properties
PropertyValueSource
logP-0.28ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area34.14 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity2.89 m3·mol-1ChemAxon
Polarizability1.53 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-a9a93dd42f2cfa0b34c4
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-a9a93dd42f2cfa0b34c4
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-a9a93dd42f2cfa0b34c4
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-5e864878b295db174473
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-5e864878b295db174473
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-9000000000-5e864878b295db174473

Taxonomy

Description
This compound belongs to the class of inorganic compounds known as other non-metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen belongs to the class of 'other non-metals'.
Kingdom
Inorganic compounds
Super Class
Homogeneous non-metal compounds
Class
Other non-metal organides
Sub Class
Other non-metal oxides
Direct Parent
Other non-metal oxides
Alternative Parents
Inorganic oxides
Substituents
Other non-metal oxide / Inorganic oxide
Molecular Framework
Not Available
External Descriptors
diatomic oxygen, elemental molecule (CHEBI:15379) / a non-metabolic compound (OXYGEN-MOLECULE)

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Agonist
Activator
General Function
Iron ion binding
Specific Function
Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Subunits 1-3 form the functional core of the enzyme complex. CO I is the catalytic su...
Gene Name
MT-CO1
Uniprot ID
P00395
Uniprot Name
Cytochrome c oxidase subunit 1
Molecular Weight
57040.91 Da
References
  1. Wilson MT, Antonini G, Malatesta F, Sarti P, Brunori M: Probing the oxygen binding site of cytochrome c oxidase by cyanide. J Biol Chem. 1994 Sep 30;269(39):24114-9. [PubMed:7929065]
  2. Thomson AJ, Greenwood C, Gadsby PM, Peterson J, Eglinton DG, Hill BC, Nicholls P: The structure of the cytochrome a3-CuB site of mammalian cytochrome c oxidase as probed by MCD and EPR spectroscopy. J Inorg Biochem. 1985 Mar-Apr;23(3-4):187-97. [PubMed:2991457]
  3. CuB-heme a3 (or heme o) binuclear centre associated with Cytochrome c oxidase subunit I as oxygen binding site [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Agonist
Activator
General Function
Voltage-gated proton channel activity
Specific Function
NOH-1S is a voltage-gated proton channel that mediates the H(+) currents of resting phagocytes and other tissues. It participates in the regulation of cellular pH and is blocked by zinc. NOH-1L is ...
Gene Name
NOX1
Uniprot ID
Q9Y5S8
Uniprot Name
NADPH oxidase 1
Molecular Weight
64870.455 Da
References
  1. Smith RG: An appraisal of potential drug interactions regarding hyperbaric oxygen therapy and frequently prescribed medications. Wounds. 2011 Jun;23(6):147-59. [PubMed:25881361]
  2. Prabhakar NR: Oxygen sensing by the carotid body chemoreceptors. J Appl Physiol (1985). 2000 Jun;88(6):2287-95. [PubMed:10846047]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.
Gene Name
HBA1
Uniprot ID
P69905
Uniprot Name
Hemoglobin subunit alpha
Molecular Weight
15257.405 Da
References
  1. Miyashita H, Hashimoto K, Mohri H, Ohokubo T, Harano T, Harano K, Imai K: Hb Kanagawa [alpha 40(C5)Lys----Met]: a new alpha chain variant with an increased oxygen affinity. Hemoglobin. 1992;16(1-2):1-10. [PubMed:1634355]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Curator comments
Binding increases the affinity of other binding sites for oxygen.
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.Spinorphin: functions as an...
Gene Name
HBB
Uniprot ID
P68871
Uniprot Name
Hemoglobin subunit beta
Molecular Weight
15998.34 Da
References
  1. Hamilton HB, Iuchi I, Miyaji T, Shibata S: Hemoglobin Hiroshima (beta-143 histidine--aspartic acid): a newly identified fast moving beta chain variant associated with increased oxygen affinity and compensatory erythremia. J Clin Invest. 1969 Mar;48(3):525-35. [PubMed:5773089]

Drug created on September 30, 2015 10:55 / Updated on November 19, 2019 16:48